Trends in MitraClip, mitral valve repair, and mitral valve replacement from 2000 to 2016

Evaluation of Changes in the Cardiac Function before and after Transcatheter Edge-to-Edge Mitral Valve Repair in Healthy Dogs: Conventional and Novel Echocardiography

“…Intraventricular pressure gradient (IVPG) was obtained from the apical four-chamber view through CMME and analyzed with homemade software in MATLAB [ 17 ]. Details of the used procedure and method of calculation of IVPG have previously been described [ 11 ]. Total IVPG, basal IVPG, and mid-to-apical IVPG were reported.…”

“…The surgical procedures to manage this condition in humans require cardiopulmonary bypass and have a high risk of complications. In human medicine, percutaneous MV repair using the MitraClip® system (Abbott Vascular, Abbott Park, IL, USA) was established in 2008 and has been demonstrated to be safe, ameliorates clinical symptoms and reduces the durations of hospitalization and mortality by addressing severe MV functional defects in high-risk surgical patients suffering from CHF [ 11 ]. Unfortunately, MitraClip is not available for use in canine patients, especially in small dogs, due to the device size.…”

Red Blood Cell Fragmentation Syndrome After Placement of MitraClip

“…The safety and efficacy of percutaneous mitral valve repair with the MitraClip system have been well established in select patients ( 1 , 2 ), and procedural volume has increased worldwide for management of patients with severe mitral regurgitation who are at high risk for cardiac surgery ( 3 , 4 ). Hemolytic anemia is a rare, but well-described complication of surgical mitral valve repair ( 5 ).…”

Commentary: More than 2 sides to the coin—the Goldilocks paradigm

“…Intrinsic alteration or pathology of this apparatus results in primary MR, whereas left ventricular dysfunction that compromises the function of the apparatus is known as secondary or functional MR. 1 Improvements in surgical technique, operative experience, and advancements in multimodality cardiac imaging have contributed to excellent short-and long-term outcomes in the clinical management of these patients. 2 In addition, there is an accelerating force, with specific minimally invasive and percutaneous transcatheter MV interventions being implemented in the larger overarching narrative of MR therapies.…”

“…Within the past 5 years, a multitude of landmark trials have compared surgical, transcatheter, and medical therapy for those with moderate to severe functional mitral regurgitation. [2][3][4][5]…”